A San Francisco biotech betting that the cholesterol statins missed is the cholesterol that still matters.
It is a Tuesday at 135 Mississippi Street. The office is small enough that everyone knows whose mug is whose. On a whiteboard near the kitchen, someone has written out the latest readout from a Phase 1b trial - a number, a confidence interval, a faint exclamation point in dry-erase blue. The number is for a drug called MAR001. The exclamation point is for what it implies.
This is Marea Therapeutics. Thirty-nine people, $190 million in the bank, one big idea about the part of cardiovascular disease that statins were never going to fix. The company is two years old. Its lead asset is in mid-stage trials. Its second asset, for acromegaly, just turned in a clean Phase 1. Nobody here is famous. The work is.
The Next Frontier of Medicines for Cardioendocrine Diseases.— Marea Therapeutics, company tagline
For four decades the cardiovascular industry has been a story about LDL. Lower the bad cholesterol. Push patients onto statins, then PCSK9 inhibitors, then siRNAs. The story works. It also leaves a stubborn residue: patients on excellent therapy whose hearts still fail them. Cardiologists call it residual risk. Marea calls it the opportunity.
The target is ANGPTL4 - a protein the body makes in fat tissue that, in effect, jams the brakes on lipoprotein lipase, the enzyme that clears triglyceride-rich particles from the blood. People born with a loss-of-function variant in ANGPTL4 have lower triglycerides, lower remnant cholesterol, and lower rates of coronary disease. Human genetics, in other words, has already done the proof-of-concept.
MAR001 is a monoclonal antibody, given by injection under the skin, that does pharmacologically what nature does genetically: blocks ANGPTL4. The Phase 1b data showed it can lower remnant cholesterol meaningfully. Phase 2b is next. Whether it becomes a drug depends on the trials, the FDA, and the long, unsentimental arithmetic of clinical development.
For now, the bet is simple. If residual cardiovascular risk has a single biggest lever, ANGPTL4 might be it. Marea is one of the few companies pulling on that lever with a clinical-stage molecule in its hand.
First-in-class subcutaneous antibody against ANGPTL4. Aims at the residual cardiovascular risk that statins and PCSK9 drugs do not address. Phase 1b showed meaningful reductions; Phase 2b is the next stop.
Long-acting antibody for acromegaly, a rare growth-hormone disorder. Positive topline Phase 1 data suggesting best-in-disease efficacy and a less burdensome dosing schedule than current options.
Earlier-stage programs driven by the same playbook: a loss-of-function variant in human genetics, an unmet need in cardiometabolic or endocrine disease, a drug designed to copy what the lucky genome already does.
Incubated inside Third Rock Ventures. Built around four scientists and one operator.
Lehrer arrived from Graphite Bio, where he had run a CRISPR-based gene-editing company. The scientific founders bring something rarer than capital: deep, decades-long fluency in human metabolism. O'Rahilly is among the world's most cited researchers in metabolic disease. Rabinowitz built the lab at Princeton that turned metabolic flux measurement into something close to routine.
- "Marea" means tide. In Spanish. In Italian. The company is named for the thing it is trying to turn.
- $190 million in venture money. Thirty-nine people on the payroll. That is roughly $4.9 million in capital per employee, which is to say: this is not a place that hires casually.
- The website tagline does not promise to cure heart disease. It says, with admirable restraint, "the next frontier of medicines for cardioendocrine diseases." Adults talking to adults.
- The cap table reads like a who's who: Sofinnova, Forbion, Perceptive Xontogeny, venBio, Third Rock, Alpha Wave, Omega, Surveyor. When that many disciplined investors agree, it usually means the science is real.
It is still Tuesday. The number is still on the whiteboard. But the floor at 135 Mississippi feels different than it did at the start of this piece, because you now know what the number means.
It means a small team of thirty-nine people has taken a hypothesis from human genetics, turned it into a molecule, put the molecule into people, and watched it move a biomarker that the cardiology field has spent twenty years pointing at. It means the second molecule, for a different disease entirely, has just cleared its first hurdle. It means the office is smaller than the cap table and the cap table is smaller than the ambition.
Nothing here is promised. Phase 2 is brutal. Phase 3 is more brutal. Drugs fail. Trials read out the wrong way. The history of cardiovascular medicine is littered with antibodies that worked in the lab and not in the world. Marea knows this. Everyone in that office knows this.
What they have is the bet, the team, the money, and the trial sites. They have the tide in the name and the tide in the trial design. Whether the tide turns is, as it always is, a question for the data. The data is on its way.